RA
MNTA

Royce & Associates’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Royce & Associates’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-608
Closed -$8K – 1302
2017
Q4 		$8K Buy
+608
New +$8.22K ﹤0.01% 1217
2015
Q1 		– Sell
-2,000
Closed -$24K – 1312
2014
Q4 		$24K Buy
+2,000
New +$22.9K ﹤0.01% 1298

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Royce & Associates's MNTA Position: Q1 2018 in Review

Royce & Associates sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2018, closing a stake of 608 shares — an estimated $8K sold.

Royce & Associates first reported a position in MNTA in Q4 2014 and held it in 2 quarters. The position peaked at $24K in Q4 2014. 163 funds tracked by Wall St. Rank hold MNTA as of Q1 2018.

  • Royce & Associates reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Royce & Associates sold 608 Momenta Pharmaceuticals, Inc. shares in Q1 2018, an estimated $8K.
  • Royce & Associates first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2014 and held it in 2 quarters.
  • Royce & Associates's Momenta Pharmaceuticals, Inc. position peaked at $24K in Q4 2014.
  • 163 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2018.

Based on Royce & Associates's 13F filing for Q1 2018, filed 14 May 2018.